{
  "success": true,
  "pagesUsed": [
    3,
    4,
    5,
    6,
    7,
    15,
    16,
    17,
    19,
    20,
    21,
    22
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Arm A: Faricimab",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Faricimab 6 mg IVT Q4W until Week 20 (Part 1), followed by Faricimab 6 mg IVT administered according to a Personalized Treatment Interval (PTI) dosing regimen (Q4W to Q16W) from Week 24 through Week 68 (Part 2).",
        "extensionAttributes": [
          {
            "url": "x-titration",
            "valueString": "true"
          },
          {
            "url": "x-doseEpochs",
            "valueString": "[{'dose': '6 mg Q4W', 'startDay': 1, 'endDay': 167, 'description': 'Part 1: Fixed Q4W dosing'}, {'dose': '6 mg PTI (Q4W-Q16W)', 'startDay': 168, 'endDay': 476, 'description': 'Part 2: Personalized Treatment Interval dosing'}]"
          }
        ]
      },
      {
        "id": "arm_2",
        "name": "Arm B: Aflibercept to Faricimab",
        "type": {
          "code": "Active Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Active Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Aflibercept 2 mg IVT Q4W until Week 20 (Part 1), followed by Faricimab 6 mg IVT administered according to a PTI dosing regimen (Q4W to Q16W) from Week 24 through Week 68 (Part 2).",
        "extensionAttributes": [
          {
            "url": "x-titration",
            "valueString": "true"
          },
          {
            "url": "x-doseEpochs",
            "valueString": "[{'dose': '2 mg Q4W', 'startDay': 1, 'endDay': 167, 'description': 'Part 1: Aflibercept active comparator period'}, {'dose': '6 mg PTI (Q4W-Q16W)', 'startDay': 168, 'endDay': 476, 'description': 'Part 2: Switch to Faricimab PTI dosing'}]"
          }
        ]
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_7"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_8"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Global Enrollment Phase",
        "instanceType": "StudyCohort",
        "characteristic": "Approximately 570 patients enrolled globally for primary analysis"
      },
      {
        "id": "cohort_2",
        "name": "China Extension",
        "instanceType": "StudyCohort",
        "characteristic": "Additional patients enrolled in mainland China, Hong Kong, or Taiwan to support local registration"
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Arm A: Faricimab - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A: Faricimab during Screening"
      },
      {
        "id": "elem_2",
        "name": "Arm A: Faricimab - Part 1 (Treatment)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A: Faricimab during Part 1 (Treatment)"
      },
      {
        "id": "elem_3",
        "name": "Arm A: Faricimab - Part 2 (Treatment)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A: Faricimab during Part 2 (Treatment)"
      },
      {
        "id": "elem_4",
        "name": "Arm A: Faricimab - Final Study Visit",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm A: Faricimab during Final Study Visit"
      },
      {
        "id": "elem_5",
        "name": "Arm B: Aflibercept to Faricimab - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B: Aflibercept to Faricimab during Screening"
      },
      {
        "id": "elem_6",
        "name": "Arm B: Aflibercept to Faricimab - Part 1 (Treatment)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B: Aflibercept to Faricimab during Part 1 (Treatment)"
      },
      {
        "id": "elem_7",
        "name": "Arm B: Aflibercept to Faricimab - Part 2 (Treatment)",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B: Aflibercept to Faricimab during Part 2 (Treatment)"
      },
      {
        "id": "elem_8",
        "name": "Arm B: Aflibercept to Faricimab - Final Study Visit",
        "instanceType": "StudyElement",
        "description": "Treatment period for Arm B: Aflibercept to Faricimab during Final Study Visit"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 8,
      "cohortCount": 2,
      "elementCount": 8
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Double Blind",
        "codeSystem": "USDM",
        "decode": "Double Blind"
      },
      "maskedRoles": [
        "Subject",
        "Investigator",
        "Outcome Assessor"
      ],
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "1:1"
      },
      "stratificationFactors": [
        "Baseline BCVA",
        "Region"
      ],
      "controlType": {
        "code": "Active Control",
        "codeSystem": "USDM",
        "decode": "Active Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Ophthalmology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Double Blind",
        "maskedRoles": [
          "Subject",
          "Investigator",
          "Outcome Assessor"
        ]
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "1:1",
        "stratificationFactors": [
          "Baseline BCVA",
          "Region"
        ]
      },
      "controlType": "Active Control",
      "therapeuticAreas": [
        "Ophthalmology"
      ]
    },
    "arms": [
      {
        "name": "Arm A: Faricimab",
        "type": "Experimental Arm",
        "description": "Faricimab 6 mg IVT Q4W until Week 20 (Part 1), followed by Faricimab 6 mg IVT administered according to a Personalized Treatment Interval (PTI) dosing regimen (Q4W to Q16W) from Week 24 through Week 68 (Part 2).",
        "isTitration": true,
        "doseEpochs": [
          {
            "dose": "6 mg Q4W",
            "startDay": 1,
            "endDay": 167,
            "description": "Part 1: Fixed Q4W dosing"
          },
          {
            "dose": "6 mg PTI (Q4W-Q16W)",
            "startDay": 168,
            "endDay": 476,
            "description": "Part 2: Personalized Treatment Interval dosing"
          }
        ]
      },
      {
        "name": "Arm B: Aflibercept to Faricimab",
        "type": "Active Comparator",
        "description": "Aflibercept 2 mg IVT Q4W until Week 20 (Part 1), followed by Faricimab 6 mg IVT administered according to a PTI dosing regimen (Q4W to Q16W) from Week 24 through Week 68 (Part 2).",
        "isTitration": true,
        "doseEpochs": [
          {
            "dose": "2 mg Q4W",
            "startDay": 1,
            "endDay": 167,
            "description": "Part 1: Aflibercept active comparator period"
          },
          {
            "dose": "6 mg PTI (Q4W-Q16W)",
            "startDay": 168,
            "endDay": 476,
            "description": "Part 2: Switch to Faricimab PTI dosing"
          }
        ]
      }
    ],
    "cohorts": [
      {
        "name": "Global Enrollment Phase",
        "characteristic": "Approximately 570 patients enrolled globally for primary analysis"
      },
      {
        "name": "China Extension",
        "characteristic": "Additional patients enrolled in mainland China, Hong Kong, or Taiwan to support local registration"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Up to 28 days prior to Day 1"
      },
      {
        "name": "Part 1 (Treatment)",
        "description": "Day 1 through Week 24; fixed Q4W dosing comparison"
      },
      {
        "name": "Part 2 (Treatment)",
        "description": "Week 24 through Week 72; PTI dosing regimen with sham to maintain masking"
      },
      {
        "name": "Final Study Visit",
        "description": "Week 72"
      }
    ]
  }
}